Quick Answer
Kalaris Therapeutics, Inc. reported Total Assets of $121.74 million for the year ending 2025.
- Kalaris Therapeutics, Inc. showed an increase of +1,875.6% in Total Assets from 2024 to 2025.
- This data is from Kalaris Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 17, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $117.85 million | Q3 2020: $393.71 million | Q1 2021: $351.28 million | Q2 2021: $327.51 million | Q3 2021: $316.53 million | Q1 2022: $231.09 million | Q2 2022: $200.00 million | Q3 2022: $293.70 million | Q1 2023: $244.04 million | Q2 2023: $282.69 million | Q3 2023: $248.31 million | Q1 2024: $144.14 million | Q2 2024: $130.99 million | Q3 2024: $122.53 million | Q1 2025: $103.09 million | Q2 2025: $92.84 million | Q3 2025: $81.18 million.
- Over the full 7 years of available data (2019 to 2025), Kalaris Therapeutics, Inc.'s Total Assets has declined by 12.7%.
- Historical annual values: Fiscal year 2025: $121.74 million | Fiscal year 2024: $6.16 million | Fiscal year 2023: $190.80 million | Fiscal year 2022: $277.08 million | Fiscal year 2021: $286.59 million | Fiscal year 2020: $370.82 million | Fiscal year 2019: $139.42 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: